Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
NovaGold Resources Fiscal Q3 Loss Widens

NovaGold Resources Fiscal Q3 Loss Widens

MT newswireMT newswire2026/10/08 12:30

08:30 AM EDT, 10/08/2026 (MT Newswires) -- NovaGold Resources (NG) reported Thursday its fiscal Q3 loss widened to $0.08 per diluted share from a loss of $0.04 a year earlier. Three analysts polled by FactSet expected a loss of $0.07. The company said it had cash and cash equivalents of $146.4 million as of Aug. 31, plus $197 million in term deposits, for total cash resources of about $343.4 million. NovaGold said it believes its cash resources are enough to complete the Donlin Gold bankable feasibility study, prepay the Barrick promissory note in Q4 and cover corporate costs for at least the next 12 months.

08:30 AM EDT, 10/08/2026 (MT Newswires) -- NovaGold Resources (NG) reported Thursday its fiscal Q3 loss widened to $0.08 per diluted share from a loss of $0.04 a year earlier. Three analysts polled by FactSet expected a loss of $0.07. The company said it had cash and cash equivalents of $146.4 million as of Aug. 31, plus $197 million in term deposits, for total cash resources of about $343.4 million. NovaGold said it believes its cash resources are enough to complete the Donlin Gold bankable feasibility study, prepay the Barrick promissory note in Q4 and cover corporate costs for at least the next 12 months.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss